Metabolic syndrome in prostate cancer: impact on risk and outcomes.

Autor:	Karzai FH; Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Madan RA; Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Dahut WL; Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Jazyk:	angličtina
Zdroj:	Future oncology (London, England) [Future Oncol] 2016 Aug; Vol. 12 (16), pp. 1947-55. Date of Electronic Publication: 2016 Apr 12.
DOI:	10.2217/fon-2016-0061
Abstrakt:	Androgen-deprivation therapy (ADT) is a fundamental element of treatment for nonlocalized prostate cancer and for patients with high-risk disease who are not candidates for radical treatment. ADT has been linked to metabolic syndrome, which involves changes in metabolic factors. While distinct from classic metabolic syndrome, this type does include changes in body composition, lipid profiles and insulin resistance. The constellation of risk factors may be associated with cardiovascular morbidity and the onset of diabetes mellitus. Physicians should discuss in detail the risk and benefits of ADT, as well as any needed lifestyle modifications with patients before beginning therapy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu